Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines

PloS One
Clement A MesedaJerry P Weir

Abstract

The robustness of immune responses to an antigen could be dictated by the route of vaccine inoculation. Traditional smallpox vaccines, essentially vaccinia virus strains, that were used in the eradication of smallpox were administered by percutaneous inoculation (skin scarification). The modified vaccinia virus Ankara is licensed as a smallpox vaccine in Europe and Canada and currently undergoing clinical development in the United States. MVA is also being investigated as a vector for the delivery of heterologous genes for prophylactic or therapeutic immunization. Since MVA is replication-deficient, MVA and MVA-vectored vaccines are often inoculated through the intramuscular, intradermal or subcutaneous routes. Vaccine inoculation via the intramuscular, intradermal or subcutaneous routes requires the use of injection needles, and an estimated 10 to 20% of the population of the United States has needle phobia. Following an observation in our laboratory that a replication-deficient recombinant vaccinia virus derived from the New York City Board of Health strain elicited protective immune responses in a mouse model upon inoculation by tail scarification, we investigated whether MVA and MVA recombinants can elicit protective respon...Continue Reading

References

Jun 26, 2003·JAMA : the Journal of the American Medical Association·Jeffrey S HalsellUNKNOWN Department of Defense Smallpox Vaccination Clinical Evaluation Team
Apr 9, 2004·Proceedings of the National Academy of Sciences of the United States of America·Linda S WyattBernard Moss
Jul 6, 2004·Journal of the American College of Cardiology·Robert E EckartUNKNOWN Department of Defense Smallpox Vaccination Clinical Evaluation Team
Nov 5, 2004·The New England Journal of Medicine·Richard T KenneyGregory M Glenn
Nov 25, 2004·Current Opinion in Biotechnology·Ingo DrexlerGerd Sutter
May 28, 2005·Journal of Virology·Koert J StittelaarAlbert D M E Osterhaus
Mar 28, 2006·Advanced Drug Delivery Reviews·Erin L Giudice, James D Campbell
Dec 16, 2006·Journal of Controlled Release : Official Journal of the Controlled Release Society·Harvinder S Gill, Mark R Prausnitz
Jan 15, 2008·Transactions of the Royal Society of Tropical Medicine and Hygiene·Nguyen Cong VienJean Lang
Mar 28, 2008·Expert Opinion on Investigational Drugs·Richard N Greenberg, Jeffrey S Kennedy
Nov 15, 2008·BMJ : British Medical Journal·Anthony HawkridgeUNKNOWN South African BCG trial team
Feb 24, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Leo L M PoonLiyanage P Perera
Apr 8, 2009·Expert Review of Vaccines·Guus F Rimmelzwaan, Gerd Sutter
Oct 20, 2009·Vaccine·Richard B KennedyGregory A Poland
Sep 30, 1935·The Journal of Experimental Medicine·T M Rivers, S M Ward
Mar 31, 2010·The Journal of Infectious Diseases·Marissa B WilckRaphael Dolin
Aug 10, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Fu-Shi QuanSang-Moo Kang
Aug 20, 2010·The Journal of General Virology·Joost H C M KreijtzGuus F Rimmelzwaan
Apr 20, 2011·Vaccine·David W PorterAdrian V S Hill
Jan 17, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Anto VrdoljakAnne C Moore
Apr 6, 2012·Expert Opinion on Drug Delivery·Sharifa Al-ZahraniRyan F Donnelly
Aug 17, 2012·Human Vaccines & Immunotherapeutics·Houda BoukhebzaGeneviève Inchauspé
Oct 10, 2012·Vaccine·Chris EdensMark R Prausnitz

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISAs
enzyme-linked immunosorbent assay
ELISA

Software Mentioned

GraphPad Prism
GraphPad
SigmaPlot

Related Concepts